Probiotic supplementation decreases intestinal transit time: meta-analysis of randomized controlled trials.
OBJECTIVE
To determine the efficacy of probiotic supplementation on intestinal transit time (ITT) and to identify factors that influence these outcomes.


METHODS
A systematic review of randomized controlled trials (RCTs) of probiotic supplementation that measured ITT in adults was conducted by searching MEDLINE and EMBASE using relevant key word combinations. Main search limits included RCTs of probiotic supplementation in healthy or constipated adults that measured ITT. Study quality was assessed using the Jadad scale. A random effects meta-analysis was performed with standardized mean difference (SMD) of ITT between probiotic and control groups as the primary outcome. Meta-regression and subgroup analyses were conducted to examine the impact of moderator variables on ITT SMD.


RESULTS
A total of 11 clinical trials with 13 treatment effects representing 464 subjects were included in this analysis. Probiotic supplementation was associated with decreased ITT in relation to controls, with an SMD of 0.40 (95%CI: 0.20-0.59, P < 0.001). Constipation (r (2) = 39%, P = 0.01), higher mean age (r (2) = 27%, P = 0.03), and higher percentage of female subjects (r (2) = 23%, P < 0.05) were predictive of decreased ITT with probiotics in meta-regression. Subgroup analyses demonstrated statistically greater reductions in ITT with probiotics in subjects with vs without constipation and in older vs younger subjects [both SMD: 0.59 (95%CI: 0.39-0.79) vs 0.17 (95%CI: -0.08-0.42), P = 0.01]. Medium to large treatment effects were identified with Bifidobacterium Lactis (B. lactis) HN019 (SMD: 0.72, 95%CI: 0.27-1.18, P < 0.01) and B. lactis DN-173 010 (SMD: 0.54, 95%CI: 0.15-0.94, P < 0.01) while other single strains and combination products yielded small treatment effects.


CONCLUSIONS
Overall, short-term probiotic supplementation decreases ITT with consistently greater treatment effects identified in constipated or older adults and with certain probiotic strains.
Miller Scientific Consulting, Inc., Arden, NC 28704, United States. larry@millerscientific.com
Larry E
LE
Miller
Arthur C
AC
Ouwehand
D000328:Adult; D000367:Age Factors; D003248:Constipation / Q000382:microbiology / Q000503:physiopathology / Q000628:therapy*; D003672:Defecation; D005260:Female; D005772:Gastrointestinal Transit; D006801:Humans; D007422:Intestines / Q000382:microbiology* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D019936:Probiotics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
Constipation; Gastrointestinal; Intestinal transit time; Meta-analysis; Probiotics